| abstract |
FIELD: chemistry. n SUBSTANCE: present invention relates to organic chemistry and specifically to compounds of formula I or pharmaceutically acceptable salts thereof, where W is where each R 4 independently denotes H or CN; R 2 denotes a cycloalkyl which can be independently substituted with two of the following substitutes: C (1-3) alkyl; Z denotes H; J denotes CH or N; X denotes or ; where R 1 denotes -OR a , -CN, -NA 1 A 2 , -SO 2 CH 3 , -COOR a , -CO 2 CH 3 , -CH 2 -NA 1 A 2 , -CONA 1 A 2 , -CH 2 OR a , -NHCH 2 CH 2 OR a , -OC (1-4) alkylNA 1 A 2 , OCH 2 CO 2 R a and tetrazolyl; R z and R y independently denotes H or -C (1-4) alkyl, where both R z may have syn or anti stereochemistry; alternatively both R z in syn interaction may be taken together to form -(CH 2 ) n -, where n equals 2; R 3 denotes C (1-3) alkyl-CF 3 or -COCH 3 ; A 1 denotes H or -C (1-4) alkyl; A 2 denotes H or -C (1-4) alkyl; alternatively, A 1 and A may be taken together with a nitrogen atom with which they are bonded to form a heterocyclic ring selected from: , where R a denotes H or C (1-4) alkyl; R bb denotes H, -C (1-4) alkyl, and -CH 2 CO 2 H, where cycloalkyl relates to a partially unsaturated ring with 6 carbon atoms. The invention also relates to specific compounds of formula I, a pharmaceutical composition based on the compound of formula I and methods of treating inflammation and autoimmune diseases. n EFFECT: novel compounds of formula I which are useful as c-fms inhibitors are obtained. n 10 cl, 2 tbl, 44 ex |